Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors

Journal for ImmunoTherapy of Cancer made the following post on X:

“New JITC article: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).”

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Authors: Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet S. Grewal, Ajita Narayan, Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J. Chisamore, Stanford L. Peng, Allison Naumovski.

Source: Journal for ImmunoTherapy of Cancer/X